Procedure type | Time period* | ||
Pre-COVID | COVID impacted | Change in cancer detection rate | |
All cancers | |||
Average cancers detected per week | 677 | 283 | |
Cancer detection rate (per 100 procedures) | 1.91 (1.86–1.95) | 6.61 (6.38–6.85) | 4.70 (4.46–4.94), p<0.001 |
Missing cancers in period | 3939 | ||
% of cancers ‘missing’ | 58.2% | ||
Number of procedures per cancer | 52 | 15 | |
Colorectal cancers (colonoscopy and flexible sigmoidoscopy) | |||
Average cancers per week | 394 | 112 | |
Cancer detection rate (per 100 procedures) | 1.97 (1.91–2.03) | 5.77 (5.44–6.10) | 3.80 (3.46–4.13), p<0.001 |
Missing cancers in period | 2828 | ||
% of cancers missing | 71.7% | ||
Number of procedures per cancer | 51 | 17 | |
Oesophageal cancers (OGD) | |||
Average cancers per week | 205 | 129 | |
Cancer detection rate (per 100 procedures) | 1.37 (1.31–1.43) | 6.16 (5.84–6.49) | 4.80 (4.47–5.13), p<0.001 |
Missing cancers in period | 759 | ||
% of cancers missing | 37.1% | ||
Gastric cancers (OGD) | |||
Average cancers per week | 61 | 29 | |
Cancer detection rate (per 100 procedures) | 0.41 (0.38–0.44) | 1.40 (1.24–1.56) | 0.99 (0.83–1.15), p<0.001 |
Missing cancers in period | 320 | ||
% of cancers missing | 52.3% | ||
Number of procedures per cancer† | 56 | 13 | |
Pancreatobiliary cancers (ERCP) | |||
Average cancers per week | 17 | 14 | |
Cancer detection rate (per 100 procedures) | 3.36 (2.77–3.74) | 5.21 (4.35–6.07) | 1.95 (0.97–2.94), p≤0.001 |
Missing cancers in period | 32 | ||
% of cancers missing | 19.2% | ||
Number of procedures per cancer | 31 | 19 |
*Difference in numbers of cancers detected in COVID-impacted period compared with number expected had the same number of weekly procedures and cancer detection rate applied as in pre-COVID period; % of cancers missed is this difference expressed as percentage of number of cancers expected.
†Pre-COVID 16 January 2020–15 March 2020; COVID-19 impacted 23 March 2020–31 May 2020.
‡Number of oesophagogastroduododenoscopy (OGD) procedures per cancer (oesophageal and gastric cancers combined).
ERCP, endoscopic retrograde cholangiopancreatography.